Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum
- 20 October 2011
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (5) , 1984-1990
Abstract
Introduction Genexol-PM is a novel Cremophor® EL (CrEL)-free polymeric micelle formulation of paclitaxel. This multicenter phase II study was designed to evaluate the efficacy and safety of Genexol-PM monotherapy in patients with advanced urothelial carcinoma who developed disease progression after gemcitabine and cisplatin combination chemotherapy. Patients and Methods Patients received Genexol-PM 240 mg/m2 intravenously over 3 h every 3 weeks without premedication. Intra-patient dose escalation to 300 mg/m2 was allowed during the second and subsequent cycles if pre-specified toxicities were not observed during the first cycle. The primary endpoint was response. Results Thirty-seven patients were enrolled in this study. Platinum-free interval was less than 6 months in 27 (73%) patients, and 24 (64%) were categorized as having intermediate or poor prognosis according to Bajorin’s criteria. Of 34 evaluable patients, there were 7 responses (21%; 95% CI, 7–34%), including one complete response (CR), with a median response duration of 6.5 months (95% CI, 3.5–9.6 months). The median time to progression was 2.7 months (95% CI, 0.9–4.6 months) with a median overall survival of 6.5 months (95% CI, 5.0–8.0 months). The most common grade 3/4 non-hematologic toxicities were peripheral neuropathy (sensory type 5.9%; motor type 8.8%) and infection (5.9%). Grade ≥3 hematologic toxicities occurred in only one patient. Conclusion Genexol-PM was generally well tolerated and demonstrated sufficient antitumor activity to warrant further development when used as second-line chemotherapy after gemcitabine-cisplatin failure in patients with urothelial carcinoma (NCT01426126).Keywords
This publication has 35 references indexed in Scilit:
- Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinomaCancer, 2009
- Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancerBreast Cancer Research and Treatment, 2007
- Peripheral neuropathy: A persisting challenge in paclitaxel-based regimesEuropean Journal of Cancer, 2006
- Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursEuropean Journal of Cancer, 2006
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micellesInternational Journal of Pharmaceutics, 2005
- Progress in the chemotherapy of metastatic cancer of the urinary tractCancer, 2003
- Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial CancerJournal of Clinical Oncology, 2002
- Cremophor ELEuropean Journal of Cancer, 2001
- Phthalate Esters and Their Effect on the LiverHepatology, 1984